Alternate Pathways Yield New Antibiotics

Scientists tinker with biosynthetic pathways to make versions of a common antibiotic that stunt drug-resistant bacteria.

Written byAmanda B. Keener
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

STATE UNIVERSITY OF NEW YORK AT BUFFALO

For decades, scientists have looked for ways to make alternate versions of antibiotics naturally produced by bacteria and fungi in hopes of expanding the activities of available drugs. In a study published today (May 29) in Science Advances, researchers from the State University of New York (SUNY) at Buffalo report a technique that allowed them to make 42 new versions of the antibiotic erythromycin, three of which showed activity against drug-resistant bacteria.

“I was going into it thinking maybe we’d make a fifth of the number [of compounds] we actually made,” said Blaine Pfeifer, a chemical and biological engineer at Buffalo, who led the study.

The bacteria Saccharopolyspora erythraea naturally produces erythromycin, but like many antibiotic-producing organisms, S. erythraea doesn’t make the best laboratory strain. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo